Updated: Eli Lilly's tirzepatide breaks into obesity market with FDA approval
Eli Lilly’s tirzepatide is officially entering the market for chronic weight management.
The drugmaker said Wednesday that the GIP/GLP-1 receptor agonist, which is known as Mounjaro for type 2 diabetes, can now be marketed as Zepbound for weight management in adults with obesity or overweight with “weight-related” health conditions.
It is set to be available in the US by the end of the year, in six doses with a list price of $1,059.87. According to Lilly, that price is about 20% lower than the list price of a 2.4 mg dose of Wegovy, Novo Nordisk’s GLP-1 for weight loss. The list price for Wegovy is $1,349.02 per package, according to Novo’s website.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.